Literature DB >> 8423098

Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection.

G A Losonsky1, C O Tacket, S S Wasserman, J B Kaper, M M Levine.   

Abstract

Peripheral blood immunoglobulin A antibody-secreting-cell (ASC) responses are thought to reflect the mucosal immune response to locally presented antigens. We evaluated the ASC response to cholera toxin (CT) and Inaba lipopolysaccharide (LPS) in 26 North American volunteers following immunization with a single oral dose of live attenuated Vibrio cholerae O1 vaccine strain CVD 103-HgR and again upon homologous wild-type challenge with V. cholerae classical Inaba 569B. Challenge occurred at either 7, 30, or 180 days after vaccination. The CT and LPS ASC responses of volunteers following vaccination (83 and 55%, respectively) were similar in magnitude and frequency to those of unvaccinated controls following wild-type challenge (80 and 60%, respectively [0.1 < or = P < or = 0.9]). The responses were primarily immunoglobulin A. Vaccinated volunteers challenged within 30 days of vaccination had reduced or nondetectable CT and LPS ASC responses. Challenge at 6 months resulted in a heightened ASC response to LPS, confirming the existence of mucosal memory. ASC responses to CT upon challenge at 6 months were detectable but not different from that seen following primary immunization, suggesting that secondary ASC responses to different antigens from a single vaccine operate independently. In spite of these variable ASC responses, the vaccine efficacy was 100% following challenge for all vaccinees. V. cholerae-specific ASC responses following antigenic reexposure gave information on the presence of mucosal B memory cells but did not correlate with protective immunity. As such, these ASC assays will have limited usefulness for evaluating vaccine responders in vaccine field trials in cholera-endemic areas where prior V. cholerae O1 exposure is unknown.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8423098      PMCID: PMC302786          DOI: 10.1128/iai.61.2.729-733.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR.

Authors:  C O Tacket; G Losonsky; J P Nataro; S J Cryz; R Edelman; J B Kaper; M M Levine
Journal:  J Infect Dis       Date:  1992-10       Impact factor: 5.226

2.  Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity.

Authors:  M M Levine; D R Nalin; J P Craig; D Hoover; E J Bergquist; D Waterman; H P Holley; R B Hornick; N P Pierce; J P Libonati
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

3.  Determinants of the localization, magnitude, and duration of a specific mucosal IgA plasma cell response in enterically immunized rats.

Authors:  N F Pierce; W C Cray
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

4.  Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine.

Authors:  A M Svennerholm; M Jertborn; L Gothefors; A M Karim; D A Sack; J Holmgren
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226

5.  Cholera antibody production in vitro by peripheral blood lymphocytes following oral immunization of humans and mice.

Authors:  N Lycke; L Lindholm; J Holmgren
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

6.  Recombinant nontoxinogenic Vibrio cholerae strains as attenuated cholera vaccine candidates.

Authors:  J B Kaper; H Lockman; M M Baldini; M M Levine
Journal:  Nature       Date:  1984 Apr 12-18       Impact factor: 49.962

7.  IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans.

Authors:  C Czerkinsky; S J Prince; S M Michalek; S Jackson; M W Russell; Z Moldoveanu; J R McGhee; J Mestecky
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

8.  Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine.

Authors:  M M Levine; R E Black; M L Clements; C Lanata; S Sears; T Honda; C R Young; R A Finkelstein
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

9.  Activation of human B lymphocytes after immunization with pneumococcal polysaccharides.

Authors:  J H Kehrl; A S Fauci
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

10.  Specific immunoglobulin-secreting human blood cells after peroral vaccination against Salmonella typhi.

Authors:  A Kantele; H Arvilommi; I Jokinen
Journal:  J Infect Dis       Date:  1986-06       Impact factor: 5.226

View more
  14 in total

Review 1.  Enteric infections, diarrhea, and their impact on function and development.

Authors:  William A Petri; Mark Miller; Henry J Binder; Myron M Levine; Rebecca Dillingham; Richard L Guerrant
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

2.  An overview of VaxchoraTM, a live attenuated oral cholera vaccine.

Authors:  Tarun Saluja; Vijayalaxmi V Mogasale; Jean-Louis Excler; Jerome H Kim; Vittal Mogasale
Journal:  Hum Vaccin Immunother       Date:  2019-09-20       Impact factor: 3.452

3.  Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral inactivated enterotoxigenic Escherichia coli vaccine.

Authors:  M Jertborn; C Ahrén; A M Svennerholm
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

4.  Validation of a gastrointestinal explant system for measurement of mucosal antibody production.

Authors:  G A Losonsky; G T Fantry; M Reymann; Y Lim
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

Review 5.  Immunology of gut mucosal vaccines.

Authors:  Marcela F Pasetti; Jakub K Simon; Marcelo B Sztein; Myron M Levine
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

6.  The utility of human challenge studies in vaccine development: lessons learned from cholera.

Authors:  Debbie-Ann T Shirley; Monica A McArthur
Journal:  Vaccine (Auckl)       Date:  2011-10

7.  Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1.

Authors:  F Qadri; C Wennerås; M J Albert; J Hossain; K Mannoor; Y A Begum; G Mohi; M A Salam; R B Sack; A M Svennerholm
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

8.  Human infection with Ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR.

Authors:  P J Cooper; M Chico; C Sandoval; I Espinel; A Guevara; M M Levine; G E Griffin; T B Nutman
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

9.  Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera.

Authors:  G A Losonsky; J Yunyongying; V Lim; M Reymann; Y L Lim; S S Wasserman; M M Levine
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

10.  Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood.

Authors:  C Ahrén; M Jertborn; A M Svennerholm
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.